Our study showed several factors of strength such as the size of the sex-balanced cohort, including unmedicated and premedicated patients and patients remitted from MDE; the assessment using three scales for depression severity; sex-separated analyses; monitoring of the treatment course; and, especially, the investigation of the three biological levels—genetics, transcription and protein for MIF. Here, MIF is linked to depressive symptom measurement.